Introduction: Hepatitis C virus (HCV) is the leading cause for liver transplantation (LT) and viral recurrence.
INTRODUCTION
End-stage liver disease secondary to chronic hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT) worldwide. 1, 2 Over the last decade, living donor liver transplantation (LDLT) has been embraced as an alternative option to increase the availability of organs and address the needs of patients who cannot await deceased donor liver transplantation (DDLT). 3 Unfortunately, HCV reinfection of the graft occurs universally, and is associated with an aggressive course in a proportion of patients, which leads to graft cirrhosis in 10 to 30% of recipients within 3 to 5 years. 4, 5 This in turn results in FOLQLFDO GHFRPSHQVDWLRQ LQ D VLJQL¿FDQW SURSRUWLRQ RI +&9 recipients who have developed cirrhosis of the allograft, with 40% developing clinical decompensation at 1 year, and up to 60% will suffer a decompensation episode 3 years after WKH GLDJQRVLV RI FLUUKRVLV 7KLV XQIRUWXQDWHO\ VLJQL¿FDQWO\ affects patient survival, with an estimated survival rate of less than 10% at 3 years. [6] [7] [8] Early reports have indicated that recurrence of HCV infection in LDLT recipients had an earlier and more aggressive clinical course compared to recurrence in the DDLT recipient. 9, 10 This phenomenon had been attributed to UDSLG JUDIW UHJHQHUDWLRQ DQG LQÀDPPDWLRQ DFFRPSDQLHG E\ poor graft function in the early postoperative period. 9 In the present study, we compared the pattern of recurrent hepatitis C, including the possible risk factors, onset, severity DQG WKH HI¿FDF\ RI +&9 WUHDWPHQW LQ ''/7 YHUVXV /'/7 recipients.
MATERIALS AND METHODS
This study was conducted in the period from January 1998 till January 2006. One hundred and eighty patients were included in the study. All patients suffered HCV-related end-stage liver disease or HCC complicating HCV-related cirrhosis. A total of 115 patients were subjected to LDLT in Dar Al Fouad Hospital, Cairo, Egypt, while 65 patients were subjected to DDLT in Leeds Hospital in England, Boukhom Hospital in Germany and Tianjin Hospital in China. Clinical, laboratory and imaging data were collected for all patients' pretransplantation. After transplantation, adverse events in the form of bouts of rejection, pulse steroid therapy, cytomegalovirus (CMV) infection, biliary complications and type of immunosuppression during this period were reported. Patients were then followed up from January 2006 till December 2008 in Police Hospital, Agouza.
The study variables included patient and donor demographics, pretransplant and post-transplant viral load, the results of synthetic liver function tests before and after living-donor liver transplant, histologic data. The laboratory data included levels of aspartate aminotransferase, alanine aminotransferase, total and direct bilirubin, serum albumin, and alkaline phosphatase, as well as prothrombin concentration, all of which were evaluated before transplant DQG GDLO\ DIWHU WUDQVSODQW GXULQJ WKH ¿UVW SRVWVXUJLFDO PRQWK then twice weekly until the end of the third postsurgical month, then monthly, and then on longer intervals thereafter. HCV RNA in serum was detected by PCR assay (Cobas Amplicor HCV test version 2.0; Roche Molecular system; lower limit of detection 50 IU/ml) before transplant, 3 months after transplant, and then whenever there is clinical indication.
Most The patients had on-treatment complete blood count and OLYHU IXQFWLRQ WHVWV DVVHVVHG ZHHNO\ LQ WKH ¿UVW ZHHNV WKHQ every 2 or 4 weeks thereafter.
RBV dose was reduced if hemoglobin levels decreased below 10 gm/dl and discontinued if hemoglobin levels were <8.5 gm/dl despite erythropoietin therapy. Erythropoietin was started in patients with hemoglobin levels below 9.5 gm/dl.
16
PEG-IFN dose was reduced to two-thirds the dose per week for platelet counts between 50,000 and 65,000/mm 3 and for leukocyte counts between 1,700 and 2,000/mm 3 and halved for platelet counts less than 50,000/mm 3 and for leukocyte counts less than 1,700/mm 3 . PEG-IFN was discontinued in cases of platelet counts <25,000/mm 3 or white blood cell counts <1,000/mm 3 .
Treatment was continued for a period of 48 weeks LQ UHVSRQGHUV 5HVSRQVH ZDV GH¿QHG DV DW OHDVW WZR ORJ decrease of the initial viral load (as estimated by quantitative PCR of HCV RNA) at week 12 and no viremia at week 24. 16 )ROORZXS 3&5 ZDV GRQH HYHU\ PRQWKV GXULQJ WKH ¿UVW year, then twice yearly in the second year, then once in the third year to ensure sustained virological response or detect any recurrence. HCV RNA was measured also whenever, clinically indicated (persistently elevated or any increase in serum ALT during therapy).
STATISTICAL ANALYSIS
Patients' data was tabulated and processed using SPSS (15.0) statistical package for Windows XP. The following patients' data were compared: before transplantation, followup after transplantation, at time of diagnosis of recurrence. (Table 4) .
Among the patients diagnosed to have hepatitis C recurrence, 21/28 (75%) and 17/31 (54.84%) patients agreed to have treatment in DDLT and LDLT groups respectively. In the DDLT group, one (3.57%) patient and in LDLT group, two (6.45%) patients discontinued treatment due to severe side effects. On comparing end of treatment response among patients who received IFN, it was found that 14 (70%) patients were responders in the DDLT group, compared to VL[ SDWLHQWV LQ WKH /'/7 JURXS ZKLFK ZDV IRXQG VWDWLVWLFDOO\ LQVLJQL¿FDQW Ȥ 2 SYDOXH !
DISCUSSION
The Egyptian National Committee on Viral Hepatitis stated that 9.8% of the Egyptians are HCV infected, whereas other UHVHDUFKHUV FODLP WKDW WKH ¿JXUH LV EHWZHHQ DQG 17 As DDLT being still not a valid option in Egypt, LDLT seemed to be the only choice to save many patients in desperate need for LT. 18 The current study was conducted to compare the pattern of recurrent hepatitis C, including the possible risk factors, ˪ RQVHW VHYHULW\ DQG WKH HI¿FDF\ RI +&9 WUHDWPHQW LQ ''/7 versus LDLT candidates.
In our study, the incidence of hepatitis C recurrence was higher in DDLT (59.57%) than LDLT (41.89%) patients. This was lower than previous studies, 7, 10, 12, 19 where a histologically diagnosed recurrence of chronic hepatitis C occurred in 65 to 90% of HCV positive DDLT recipients GXULQJ WKH ¿UVW \HDUV DIWHU VXUJHU\ ,Q WKH FXUUHQW VWXG\ recurrence occurred within a time range from 3 to 38 months in DDLT group, while in LDLT group, it ranged from 1 to 39 months. This comes in agreement with the study done by Guo et al, 20 where histological evidence of recurrent hepatitis occurred at 4 months and reached 90% 1 year post-LT. In the DDLT group, nine patients showed low viremia, and 19 patients showed high viremia compared to 11 and 20 patients respectively in the LDLT group. The higher level and activity of HCV may be due to rapid regeneration of the liver in LDLT group making the cells more prone to reinfection and their activity enhances the viral introduction and replication. 21 Immunosuppression is considered a main factor in the severity of recurrent HCV infection, 22, 23 because of its effect on viral replication and its suppression of systemic immune responses, both of which can lead to accelerated KHSDWRFHOOXODU GDPDJH DQG ¿EURVLV In our study, tacrolimus and cyclosporine were not associated with HCV recurrence. Cyclosporine had antiviral properties in vitro DQG ZDV DVVRFLDWHG ZLWK D VLJQL¿FDQWO\ lower risk of recurrence of HCV 24 and less fibrosis. 25 However, no compelling data suggested that there was an advantage to using either tacrolimus or cyclosporine in clinical practice. 26, 27 In DDLT group, pulse steroid therapy ZDV VLJQL¿FDQWO\ UHODWHG WR +&9 UHFXUUHQFH S This might be due to the increased use of pulse steroid to treat rejection which was encountered more in this group (possibly due to prolonged ischemia time). Our results were similar to previous studies. 20 In contrast, Yosry et al 28 suggested that immunosuppressive therapy and pulse steroid therapy were not associated with HCV recurrence. Due to the fact that CMV has immunomodulating properties, it was presumed that reactivation of CMV could accelerate HCV pathogenesis in critically ill patients. 29 This came in agreement with our results that CMV coinfection ZDV VLJQL¿FDQWO\ FRUUHODWHG ZLWK +&9 UHFXUUHQFH LQ /'/7 group. On the contrary, a recent study showed that CMV coinfection was not associated with HCV recurrence. 30 Moreover, Nebbia et al 31 proved in his study that HCVinfected patients with CMV DNAemia were not at increased ULVN RI OLYHU ¿EURVLV DW \HDU SRVWWUDQVSODQWDWLRQ 6HYHULW\ RI UHFXUUHQFH ZDV DVVHVVHG E\ ¿EURVLV DQG activity scores in liver biopsy, where the LDLT group showed significantly higher grade of fibrosis (2.227 ± DQG LQÀDPPDWLRQ WKDQ ''/7 JURXS (1.669 ± 1.532 and 4.846 ± 2.483 respectively) (p < 0.001). This might be due to higher cellular activity in the LDLT JURXS UHÀHFWLQJ WKH QHHG RI WKH KHSDWRF\WHV WR UHJHQHUDWH so they are more prone to be reinfected by HCV. 9 In the current study, treatment with pegylated IFN and RBV was started in 75% of DDLT patients and 54.84% of LDLT patients. Patients who did not receive therapy deliberately decided to postpone it and to be followed up.
Three patients (one in DDLT group and two in LDLT group) dropped out during therapy due to serious side effects. This was similar to the results of the study conducted by Iacob et al 34 where 11 to 37% of patients discontinued the therapy.
Among those who completed the therapy, 70% of DDLT group and 40% of LDLT group achieved end of treatment response (ETR) after 48 weeks of therapy. These results were in agreement with other studies. 35 From this study, we could conclude that the incidence of hepatitis C recurrence is higher in DDLT but the severity is more in LDLT. Pulse steroid therapy and CMV were related to recurrence in DDLT and LDLT respectively. While diabetes mellitus, preoperative viral load and the use of tacrolimus or cyclosporine as immunosuppressant did not affect recurrence.
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